172 related articles for article (PubMed ID: 19383812)
1. Utility of p16 immunohistochemistry for the identification of Lynch syndrome.
Payá A; Alenda C; Pérez-Carbonell L; Rojas E; Soto JL; Guillén C; Castillejo A; Barberá VM; Carrato A; Castells A; Llor X; Andreu M; Koh J; Enders GH; Benlloch S; Jover R
Clin Cancer Res; 2009 May; 15(9):3156-62. PubMed ID: 19383812
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
[TBL] [Abstract][Full Text] [Related]
3. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
[TBL] [Abstract][Full Text] [Related]
4. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.
Pérez-Carbonell L; Alenda C; Payá A; Castillejo A; Barberá VM; Guillén C; Rojas E; Acame N; Gutiérrez-Aviñó FJ; Castells A; Llor X; Andreu M; Soto JL; Jover R
J Mol Diagn; 2010 Jul; 12(4):498-504. PubMed ID: 20489114
[TBL] [Abstract][Full Text] [Related]
5. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
[TBL] [Abstract][Full Text] [Related]
6. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
9. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.
Rahner N; Friedrichs N; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
J Pathol; 2008 Jan; 214(1):10-6. PubMed ID: 17973250
[TBL] [Abstract][Full Text] [Related]
10. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
[TBL] [Abstract][Full Text] [Related]
11. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
12. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
13. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
[TBL] [Abstract][Full Text] [Related]
14. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
[TBL] [Abstract][Full Text] [Related]
15. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
17. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Goel A; Xicola RM; Nguyen TP; Doyle BJ; Sohn VR; Bandipalliam P; Rozek LS; Reyes J; Cordero C; Balaguer F; Castells A; Jover R; Andreu M; Syngal S; Boland CR; Llor X
Gastroenterology; 2010 May; 138(5):1854-62. PubMed ID: 20102720
[TBL] [Abstract][Full Text] [Related]
18. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
19. "Null pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation.
Hagen CE; Lefferts J; Hornick JL; Srivastava A
Am J Surg Pathol; 2011 Dec; 35(12):1902-5. PubMed ID: 22067334
[TBL] [Abstract][Full Text] [Related]
20. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
Alemayehu A; Sebova K; Fridrichova I
Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
